Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation

Leuk Lymphoma. 2022 Mar;63(3):755-758. doi: 10.1080/10428194.2021.2002319. Epub 2021 Nov 15.

Authors

Martin Jädersten^{1

2}, Ksenia Boriskina³, Carolin Lindholm^{1

2}, Simone Weström⁴, Lucia Cavelier⁴, Eva Hellström-Lindberg^{1

2}, Stephan Mielke³, Magnus Tobiasson^{1

2}

Affiliations

¹ Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
² Center for Hematology and Regenerative Medicine, Insitution for Medicine, Huddinge, Sweden.
³ Centre for Allogeneic Stem Cell Transplantation, Stockholm, Sweden.
⁴ Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala Universitet, Uppsala, Sweden.

PMID: 34775885
DOI: 10.1080/10428194.2021.2002319

No abstract available

Publication types

Letter

MeSH terms

Azacitidine / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute*
Sulfonamides / therapeutic use

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
Azacitidine
venetoclax